S-1/A: Alumis Inc. Eyes Nasdaq Debut with $274 Million IPO to Advance TYK2 Inhibitors

Alumis Inc. is set to launch its IPO, aiming to raise $274 million to fuel the clinical development of its TYK2 inhibitors, ESK-001 and A-005, targeting immune-mediated diseases.

Summary

• Alumis Inc., a clinical-stage biopharmaceutical company, is planning an initial public offering (IPO) to raise approximately $274 million.
• The company intends to offer 17,650,000 shares of common stock, with an estimated initial public offering price between $16.00 and $18.00 per share.
• The primary goal of the IPO is to fund the clinical development of Alumis's two lead Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001 and A-005.
• ESK-001 is being developed for the treatment of moderate-to-severe plaque psoriasis (PsO) and systemic lupus erythematosus (SLE).
• A-005 is a central nervous system (CNS) penetrant molecule being developed for neuroinflammatory and neurodegenerative diseases.
• The company expects to report results from its Phase 2 clinical trial of ESK-001 in SLE in 2026.
• Alumis plans to initiate Phase 3 clinical trials of ESK-001 in PsO in the second half of 2024.
• Initial results from the Phase 1 program of A-005 in healthy volunteers are expected by the end of 2024.
• The company has raised more than $600 million to date and is backed by established life science investors.
• Alumis intends to list its common stock on the Nasdaq Global Market under the symbol ALMS.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both the potential of the company's drug candidates and the risks associated with drug development and commercialization. The positive clinical data and experienced management team contribute to a moderately positive sentiment.

Positives

• ESK-001 has demonstrated significant therapeutic effect in a Phase 2 program in patients with PsO.
• Interim OLE data for ESK-001 in PsO showed 93% of evaluable patients achieving PASI 75 at the 40 mg BID dose after 28 weeks of treatment.
• A-005 has demonstrated protective effects in prophylactic and therapeutic in vivo EAE models of neuroinflammation.
• The company has assembled an experienced executive team and is backed by established blue-chip life science investors.

Negatives

• The company has a limited operating history and no products approved for commercial sale.
• Alumis has incurred substantial losses since its inception and anticipates incurring substantial and increasing losses for the foreseeable future.
• The company's consolidated financial statements contain a statement regarding a substantial doubt about its ability to continue as a going concern.

Risks

• The company will require substantial additional financing to achieve its goals.
• Preclinical and clinical development involves a lengthy and expensive process, with an uncertain outcome.
• Clinical trials may reveal significant adverse events not seen in preclinical studies.
• The company faces competition from entities that have made substantial investments into the rapid development of competitor treatments.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable.
• The company is dependent on the services of its management team and other clinical and scientific personnel.
• If the company is unable to obtain and maintain sufficient intellectual property protection, competitors could develop and commercialize similar products.
• The company may have conflicts with any future licensors or collaborators.

Future Outlook

The company plans to use the net proceeds from the IPO to fund clinical development and related studies for its product candidates, as well as activities in preparation for such clinical development.

Industry Context

The document highlights the competitive landscape in the treatment of immunological indications, noting competition from large and specialty pharmaceutical and biotechnology companies. It also discusses the increasing emphasis on cost-containment initiatives in healthcare, which may put pressure on the pricing and usage of the company's product candidates.

Comparison to Industry Standards

• The document compares ESK-001's Phase 2 clinical data in PsO to existing biologic therapies, noting response rates in the range observed with these therapies.
• It also mentions Otezla and Sotyktu as competing oral therapeutics for PsO, and discusses the AEs and SAEs related to JAK inhibition, such as cardiovascular and thrombotic events, observed in other TYK2 inhibitors like deucravacitinib (Sotyktu).

Related Party Transactions

• The company has a services agreement with Foresite Labs, an entity affiliated with Foresite Capital Management, a holder of more than 5% of the company's outstanding capital stock.
• In February 2021, the company issued and sold shares of Series Seed redeemable convertible preferred stock to entities affiliated with Foresite Capital Management, a holder of more than 5% of the company's outstanding capital stock.
• In March 2021, the company issued and sold shares of Series A redeemable convertible preferred stock to entities affiliated with Foresite Capital Management, a holder of more than 5% of the company's outstanding capital stock.
• In March 2021, the company issued convertible promissory notes to entities affiliated with Foresight Capital Management, a holder of more than 5% of the company's outstanding capital stock.
• In multiple closings between December 2021 and January 2022, the company issued and sold shares of Series B and Series B-1 redeemable convertible preferred stock to AyurMaya Capital Management Fund, LP, entities affiliated with BBA, and entities affiliated with Foresite Capital Management.
• In May 2023 and October 2023, the company issued and sold shares of Series B-2 and Series B-2A redeemable convertible preferred stock to AyurMaya Capital Management Fund, LP, entities affiliated with BBA, and entities affiliated with Foresite Capital Management.
• In March and May 2024, the company issued and sold shares of Series C redeemable convertible preferred stock to AyurMaya Capital Management Fund, LP, entities affiliated with BBA, entities affiliated with Foresite Capital Management, Samsara BioCapital, LP, and venBio Global Strategic Fund IV, L.P.

Stakeholder Impact

• Shareholders: The IPO will provide an opportunity for new investors to participate in the company's growth, while existing shareholders may experience dilution.
• Employees: The company's success will depend on its ability to attract, retain, and motivate highly qualified personnel.
• Patients: The company's mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.
• Creditors: The company's ability to repay its debts will depend on its ability to generate revenue and raise additional capital.

Next Steps

• Initiate multiple Phase 3 clinical trials of ESK-001 in PsO in the second half of 2024.
• Report top-line results for the Phase 2b clinical trial of ESK-001 in SLE in 2026.
• Report initial results from the Phase 1 program of A-005 in healthy volunteers by the end of 2024.
• Seek regulatory approval for ESK-001 and A-005 in various indications.
• Evaluate strategic collaborations to maximize the global impact of product candidates.

Key Dates

Keywords

TYK2 inhibitors, ESK-001, A-005, IPO, Psoriasis, Systemic Lupus Erythematosus, Clinical trials, Biopharmaceutical, Immunology, Drug development